Herbal drugs constitute a significant proportion of global therapeutic interventions, yet their clinical application remains constrained by substantial variability in phytochemical composition, manufacturing processes, and therapeutic outcomes. This comprehensive analysis examines the multifaceted challenges inherent in the standardization and quality control of herbal formulations, with particular emphasis on batch-to-batch consistency, analytical methodologies, and regulatory frameworks. The intrinsic variability of botanical materials arising from genetic diversity, environmental factors, harvesting protocols, and post-harvest processing significantly impacts the reproducibility of therapeutic efficacy. Contemporary standardization techniques including high-performance liquid chromatography, gas chromatography-mass spectrometry, and spectroscopic methods are critically evaluated for their capacity to ensure phytochemical consistency. Real-world examples from commercially available herbal products demonstrate coefficient of variation ranges from 15 to 45 percent in marker compound content across different production batches, highlighting the urgent need for stringent quality control measures. Regulatory disparities between the European Medicines Agency, United States Food and Drug Administration, and traditional medicine systems further complicate global harmonization efforts. Statistical evidence from clinical trials reveals that standardized herbal preparations exhibit significantly improved therapeutic predictability compared to non-standardized counterparts, with effect size variations of 30 to 60 percent. Future directions emphasize the integration of metabolomics, artificial intelligence-driven quality prediction, and international regulatory convergence to establish evidence-based herbal therapeutics that meet pharmaceutical-grade standards while preserving traditional knowledge systems.